Helix has been selected as the multiomics laboratory and AI tools provider for Precure, a newly launched Mayo Clinic initiative aimed at generating molecular data from approximately one million biospecimens. The partnership positions Helix as a key infrastructure provider for one of healthcare's most ambitious efforts to integrate genomic and proteomic insights into routine clinical practice.

Precure, launched by Mayo Clinic with founding partner Thermo Fisher Scientific, aims to make clinical whole genome sequencing a foundation of care, potentially enabling disease detection before symptoms appear. As part of the collaboration, Helix becomes a minority owner in Precure and will provide CLIA/CAP-certified genomic sequencing, workflow orchestration, data infrastructure, and AI tools to support the initiative's population-scale ambitions.

Building on Proven Success

The partnership builds on an established relationship between Helix and Mayo Clinic. Mayo's Tapestry study, which reached 100,000 participants, utilized Helix's Exome+ sequencing technology. According to Dr. Aaron Mangold, Chief Medical Officer of Precure, the company sought a partner capable of delivering both clinical whole genome sequencing and research-grade proteome sequencing at scale.

"We needed a partner who could provide not just laboratory services, but the complete infrastructure—from sequencing to AI-driven analysis tools—required to integrate molecular insights into clinical workflows," Mangold stated in the announcement.

For the Precure initiative, Helix will deploy Ultima Genomics' UG200™ Ultra Sequencing Platform to generate large-scale multiomics data. The technology selection reflects the initiative's need for high-throughput capabilities to process molecular data from approximately one million biospecimens.

Strategic Positioning in Precision Medicine Infrastructure

The deal signals Helix's evolution from its direct-to-consumer genomics origins to becoming essential AI-enabled laboratory infrastructure for health systems pursuing precision medicine at scale. Dr. James Lu, CEO of Helix, emphasized the company's comprehensive capabilities in supporting population genomics initiatives.

"Our CLIA/CAP-certified laboratory services combined with advanced AI tools position us to support health systems as they move from pilot studies to population-scale implementation of genomic medicine," Lu stated.

For healthcare providers, the partnership establishes a framework for integrating population-scale genomic and proteomic data into routine clinical workflows. The initiative aims to enable earlier disease detection and precision medicine approaches that could extend beyond Mayo Clinic to other health systems.

Financial returns to Mayo Clinic from the Precure initiative will be reinvested in the institution's patient care, research, and education mission, according to the announcement.

Implications for the Genomics Industry

Helix's selection validates the commercial viability of combining certified laboratory services with AI-driven genomic analysis tools. Competitors in the clinical genomics and AI-driven diagnostics space will need to demonstrate similar capabilities for workflow orchestration and data infrastructure at population scale to compete for health system partnerships.

For patients, the initiative represents a potential shift toward making whole genome sequencing a routine part of clinical care, creating opportunities for preventive interventions based on molecular insights linked to longitudinal health records.

Sources

  1. Precure Selects Helix as Multiomics Lab and AI Tools Provider — GEN – Genetic Engineering & Biotechnology News